Onward Therapeutics Raises NT$900 Million in Series B to Advance Oncology Pipeline

Onward Therapeutics closed NT$900 million, roughly $28 million, in Series B financing to advance its clinical-stage cancer programs, the company announced.

The round was completed in two closings, with the second occurring in October 2026. The funds support its clinical-stage cancer programs, clinical-supply manufacturing, and early research.

The raise matters to patients because it keeps two experimental therapies moving through early-phase trials: a bispecific antibody for solid tumors and blood cancers, and an off-the-shelf natural killer cell therapy being tested in France against a hard-to-treat lymphoma. This is Onward’s first fundraising effort since it finalized a share swap and relocated its worldwide head office from Switzerland to Taiwan in October 2025.

Before that transaction, Onward had raised CHF 75.5 million, or approximately $90 million, through earlier rounds. Backers include returning shareholders such as CDIB Capital Healthcare Ventures and Hong Kong Chlitina International, joined by new institutional participants — Beiley Biofund, Everbright Biofund, Test Rite International Co., Ltd., Grand Fortune Venture Capital, Hercules Bioventure Partners, MitoBitTech Venture, and Top Taiwan Venture Capital — alongside individual investors, per the company’s announcement distributed via PR Newswire.

“This financing, our first since establishing our global headquarters in Taiwan, allows us to advance our clinical programs while building our R&D presence here,” said Dr. C. Grace Yeh, Chairperson and CEO of Onward Therapeutics, in the company’s release.

Onward Therapeutics Raises NT$900 Million in Series B to Advance Oncology Pipeline
Photo: morningstar.com

Funding News, Not Approval News

  • This is funding news, not approval news. Nothing here changes what treatment any patient can access today.
  • Both therapies are in Phase 1 trials — the earliest stage of human testing, designed mainly to check safety and dosing, not to prove the drugs work.
  • Early tumor responses reported by the company are preliminary observations, and the company itself says they need confirmation in larger trials.

What OT-A201 Is Designed to Do

OT-A201, a tetravalent bispecific antibody, was engineered to tackle several different pathways through which tumors dodge or resist the immune system.

In plain terms, a bispecific antibody is an engineered protein built to grab two different targets at once — here, designed to counter multiple mechanisms by which tumors evade or resist immune attack. “Tetravalent” means it has four binding arms, which the company says lets it address complementary routes of immune evasion.

In solid tumors, the company said the program has completed monotherapy dose escalation — the careful, step-by-step process of finding how much of a drug can be given safely — and advanced into Phase 1b development. Planned work includes expansion cohorts in selected cancer types and combination regimens.

In blood cancers, or hematologic malignancies, Onward expects to complete enrollment in a Phase 1a study by the end of 2026. Preliminary findings include tumor shrinkage and stabilized disease, along with a safety profile the company characterized as manageable. These are early clinical observations and require confirmation through additional trials, the company said.

The NK Cell Therapy Aimed at Relapsed Lymphoma

The second clinical program, OT-C001, is an off-the-shelf natural killer cell therapy derived from umbilical cord blood. “Allogeneic” means the cells come from a donor rather than the patient themselves — which is what makes the therapy off-the-shelf: it can be manufactured in advance and given without the weeks-long personalization that CAR-T therapies require.

In France, the therapy is being studied alongside rituximab in diffuse large B-cell lymphoma patients whose disease returned after, or failed to respond to, CAR-T and T-cell engager therapies — a population left with almost no remaining treatment choices.

CAR-T therapy is a treatment where a patient’s own T cells are genetically engineered to attack cancer; T-cell engagers are antibody drugs that pull T cells toward tumor cells. Patients whose disease returns after both have few approved choices left.

The company said preliminary results indicate a favorable safety profile, and several cases of complete metabolic response have been observed — meaning scans showed no signs of active cancer. Enrollment and follow-up are ongoing, and the company’s own release notes these are preliminary findings.

How the Two Programs Compare

Program Type Stage and setting Early findings per company
OT-A201 Tetravalent bispecific antibody Phase 1b in solid tumors; Phase 1a in blood cancers, enrollment closing by end of 2026 Tumor responses and disease stabilization; manageable safety profile
OT-C001 Allogeneic NK cell therapy from cord blood Phase 1 in France, combined with rituximab, for relapsed/refractory DLBCL Favorable safety profile; several complete metabolic responses

Company-Funded Research, No Independent Verification

The company said Series B proceeds will go toward advancing its clinical programs, producing clinical trial materials, and financing early-stage R&D. The underlying pipeline research to date has been financed by Onward’s own investors — roughly $90 million raised before the Taiwan share exchange and now this $28 million round.

That matters for transparency: the trial results reported so far come from the company developing the drugs, not from independent investigators, and no peer-reviewed publication of the Phase 1 data is cited in the announcement.

Early-stage programs include an oncology metabolism project and an antibody targeting tumor-associated antigens, per the release: a small-molecule project in onco-metabolism — how tumors rewire their metabolism to grow — and an antibody program against tumor-associated antigens, molecules found on cancer cells, with what the company called potential first-in-class characteristics. Neither has reached human trials.

Dr. Armand de Gramont, one of the Company’s three co-founders, was elevated in April 2026 from Chief Scientific Officer to the role of President of R&D, according to the company’s release.

“Our priority is to translate innovative science into meaningful clinical results,” he said. “By focusing on indications where our therapies have the greatest potential to overcome treatment resistance, we aim to build a differentiated oncology pipeline to deliver new treatment options for patients.”

“Many patients with difficult-to-treat or relapsed cancers still have limited treatment options. We aim to bring them new options through different types of cancer therapies,” Yeh said in the release.

Next Steps in Taiwan and the Taipei Exchange

By the end of 2027, Onward intends to list on the Taipei Exchange’s Emerging Stock Board. It also plans to expand its Taiwan team and begin local clinical trials. For Taiwan’s biotech sector, the round adds institutional backing from seven new venture funds to a company that relocated its headquarters from Switzerland just over a year ago.

For patients elsewhere, the practical significance is narrower: the OT-C001 trial is running in France, and the OT-A201 trials’ locations were not specified in the announcement.

Whether either therapy eventually reaches regulatory review before the FDA or the EMA — the European regulator now overseeing the French trial’s jurisdiction — depends on data that does not yet exist. Phase 1 programs frequently fail to advance; the company has reported no efficacy statistics, only preliminary observations.

No Patient Can Access These Therapies Outside Trials

Neither OT-A201 nor OT-C001 is approved or commercially available, so no patient can request or receive them outside an enrolled clinical trial. Patients with relapsed diffuse large B-cell lymphoma who have already received CAR-T or T-cell engager therapy should discuss trial eligibility — including prior-treatment restrictions, organ function requirements and travel to trial sites — with their treating oncologist.

Anyone experiencing progressive symptoms such as rapidly enlarging lymph nodes, unexplained fevers, night sweats or weight loss should seek prompt medical evaluation. Patients should be wary of any clinic offering these unapproved therapies outside a registered trial.

The next dated milestone the company has given is the expected completion of Phase 1a enrollment in blood cancers by the end of 2026 — within weeks of this announcement.

Photo of author

Health Desk

Health Desk at Archyde.

China Scraps Tariffs; Africa Trade Deficit Jumps 34% to $80bn